Leaflet: Information for the User
Pirfenidona Kern Pharma 267mg Film-Coated Tablets
Pirfenidona Kern Pharma 534mg Film-Coated Tablets
Pirfenidona Kern Pharma 801mg Film-Coated Tablets
Read this leaflet carefully before you start taking this medicine,because it contains important information for you.
1.What Pirfenidona Kern Pharma is and what it is used for
2.What you need to know before you start taking Pirfenidona Kern Pharma
3.How to take Pirfenidona Kern Pharma
4.Possible side effects
5.Storage of Pirfenidona Kern Pharma
6.Contents of the pack and additional information
This medication contains the active ingredient pirfenidona and is used for the treatment of Idiopathic Pulmonary Fibrosis (IPF) in adults.
IPFis a disease in which the lung tissues become swollen and filled with scars over time, making it difficult to breathe deeply. In these circumstances, the lungs have trouble functioning correctly. This medication helps to reduce lung scarring and swelling, and helps you breathe better.
Do not take Pirfenidona Kern Pharma
If any of the above applies to you, do not take this medication. If you have any doubts, consult your doctor or pharmacist.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Pirfenidona Kern Pharma
This medication may cause severe liver problems. Some cases have been fatal. You will need to have blood tests before starting to take Pirfenidona Kern Pharma, once a month for the first 6 months, and then every 3 months while taking this medication, to check the proper functioning of your liver. It is essential to have these blood tests periodically throughout the time you are taking this medication.
Children and adolescents
Do not administer this medication to children and adolescents under 18 years old.
Other medications and Pirfenidona Kern Pharma
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
This is especially important if you are taking the following medications, as they may alter the effect of Pirfenidona Kern Pharma.
The following medications may increase the side effects of pirfenidona:
The following medications may reduce the effectiveness of pirfenidona:
Taking Pirfenidona Kern Pharma with food and drinks
Do not drink grapefruit juice while taking this medication. Grapefruit juice may make this medication not work correctly.
Pregnancy and breastfeeding
As a precaution, it is recommended to avoid using this medication if you are pregnant, planning to become pregnant, or think you may be pregnant, as the potential risks to the fetus are unknown.
If you are breastfeeding or plan to breastfeed, talk to your doctor or pharmacist before taking this medication. As it is not known whether pirfenidona is excreted in breast milk, your doctor will explain the risks and benefits of taking this medication during breastfeeding if you decide to do so.
Driving and operating machinery
Do not drive or operate machinery if you feel dizzy or tired after taking this medication.
Pirfenidona Kern Pharma contains lactose and sodium
This medication contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
This medication contains less than 1mmol of sodium (23mg) per tablet, which is essentially "sodium-free".
The treatment with this medication should be initiated and supervised by specialist doctors with experience in the diagnosis and treatment of FPI.
Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
This medication will normally be administered by gradually increasing the dose as follows:
The recommended daily maintenance dose ofthis medicationis 801mg (3 yellow tablets or 1 brown tablet) three times a day with food, a total of 2.403mg/day.
Swallow the tablets whole with water, during or after a meal to reduce the risk of side effects such as nausea (feeling of discomfort) and dizziness. If symptoms persist, consult your doctor.
Reduction of the dose due to side effects
Your doctor may decide to reduce the dose if you experience side effects such as stomach problems, skin reactions to sunlight or UV-A lamps, or significant changes in liver enzymes.
If you take more Pirfenidona Kern Pharma than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Pirfenidona Kern Pharma
If you forget to take a dose, take it as soon as you remember. Do not take a double dose to compensate for the missed doses. Each dose should be separated by a minimum interval of 3 hours. Do not take more tablets per day than correspond to your prescribed daily dose.
If you interrupt treatment with Pirfenidona Kern Pharma
In certain situations, your doctor will advise you to stop taking this medication. If for any reason you stop taking Pirfenidona Kern Pharma for more than 14 consecutive days, the doctor will restart your treatment with a dose of 267mg 3 times a day and will gradually increase it to 801mg 3 times a day.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Stop taking Pirfenidona Kern Pharma and seek medical attention immediately if you notice any of the following symptoms or signs
Other possible side effects are
If you experience any type of side effect, consult your doctor.
Frequent side effects(may affect more than 1 in 10 people):
Common side effects(may affect up to 1 in 10 people):
Rare side effects(may affect up to 1 in 100 people):
Reporting side effects
If you experienceany type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possibleside effect that does not appear in this prospectus.You can also report them directly through the Spanish System of Pharmacovigilance of Medicines for Human Use:www.notificaRAM.es.By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the blister pack and on the box after CAD. The expiration date is the last day of the month indicated.
This medication does not require special conditions for conservation.
Medications should not be disposed of through drains or in the trash. Dispose of packaging and medications you no longer need at the SIGRE point of your pharmacy. Ask your pharmacist how to dispose of packaging and medications you no longer need. This will help protect the environment.
Pirfenidona Kern Pharma Composition
Tablets of 267mg
Tablet Core: lactose, sodium croscarmellose, anhydrous colloidal silica, magnesium stearate.Tablet Coating:poly(vinyl alcohol), titanium dioxide (E171), macrogol, talc, and yellow iron oxide (E172).
Tablets of 534mg
Tablet Core: lactose, sodium croscarmellose, anhydrous colloidal silica, magnesium stearate.Tablet Coating:poly(vinyl alcohol), titanium dioxide (E171), macrogol, talc, yellow iron oxide (E172), and red iron oxide (E172).
Tablets of 801mg
Tablet Core: lactose, sodium croscarmellose, anhydrous colloidal silica, magnesium stearate.Tablet Coating:poly(vinyl alcohol), titanium dioxide (E171), macrogol, talc, red iron oxide (E172), and black iron oxide (E172).
Appearance of the Product and Contents of the Package
Tablets of 267mg
Pirfenidona Kern Pharma 267mg film-coated tablets are yellow, oval, biconvex film-coated tablets with the inscription “267”.
The packages contain single-dose blisters with 21, 63, or 252 film-coated tablets.
Tablets of 534mg
Pirfenidona Kern Pharma 534mg film-coated tablets are orange, oval, biconvex film-coated tablets with the inscription “534”.
The packages contain single-dose blisters with 21 or 84 film-coated tablets.
Tablets of 801mg
Pirfenidona Kern Pharma 801mg film-coated tablets are brown, oval, biconvex film-coated tablets with the inscription “801”.
The packages contain single-dose blisters with 84 film-coated tablets.
Marketing Authorization Holder
Kern Pharma, S.L.
Venus, 72 – Pol. Ind.Colón II
08228 Terrassa – Barcelona
Spain
Responsible for Manufacturing
Rontis Hellas, Medical and Pharmaceutical Products S.A.
P.O. Box 3012, Larissa Industrial Area
41500 Larissa
Greece
or
PharOS MT Ltd.
HF62X, Hal Far Industrial Estate,
Birzebbugia BBG3000
Malta
Last Review Date of this Leaflet:January 2024
The detailed information of this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/)
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.